BCL2 and breast carcinoma: Knowlton et al. have reported that the overexpression of Bcl-2 in breast cancer cells slowed their in vitro growth despite their anti-apoptotic potential that protected cells against doxorubicin, and was predicted to yield favourable outcome in cancer control [46].